Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

OBJECTIVES. Trastuzumab (H) and pertuzumab (P) with standard chemotherapy is approved for use in the neoadjuvant setting for human epidermal growth receptor 2 ‐positive patients. A retrospective analysis was performed of patients treated with dose‐dense (dd) doxorubicin and cyclophosphamide (AC) fol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Singh, Jasmeet C., Mamtani, Anita, Barrio, Andrea, Morrow, Monica, Sugarman, Steven, Jones, Lee W., Yu, Anthony F., Argolo, Daniel, Smyth, Lilian M., Modi, Shanu, Schweber, Sarah, Boafo, Camilla, Patil, Sujata, Norton, Larry, Baselga, Jose, Hudis, Clifford A., Dang, Chau
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330708/
https://ncbi.nlm.nih.gov/pubmed/28167568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0268
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars